Mirati Therapeutics has selected ZoBio to provide fragment-based screening, biophysical compound characterization and structural biology for several oncology targets. In this arrangement, ZoBio screens its fragment library using both its proprietary Target Immobilized NMR Screening and SPR capabilities…
Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms
MILAN, IT, AND LEIDEN, NL
Axxam and ZoBio have initiated a strategic alliance to provide a combination of integrated discovery services spanning all phases from gene to fully optimized leads.
This alliance provides access to a synergistic, industry-leading…
Gotham Therapeutics and ZoBio Achieve Significant Milestone in Epitranscriptomic Drug Discovery Collaboration
NEW YORK, NY, USA AND LEIDEN, NL
Gotham Therapeutics has selected ZoBio to initiate a collaboration on the development of small molecules targeting epitranscriptomic targets. This collaboration has now resulted in several lead candidates for the METTL3/METTL14 complex…